Ajax Therapeutics Secures $95M Series C to Pioneer Next-Gen JAK2 Inhibitor Therapies for Myelofibrosis Patients

Ajax Therapeutics is thrilled to announce a groundbreaking funding milestone, having raised $95 million to propel its innovative research in hematologic cancers into the next phase. This significant investment underscores the high level of confidence from our partners and investors in our uniquely selective approach to tackling myeloproliferative neoplasms (MPNs), including myelofibrosis—a disease that continues to pose major challenges to patients and healthcare providers alike. By leveraging decades of deep cancer and structural biology insights from our founding scientists alongside state-of-the-art computational drug discovery and protein structure platforms, Ajax is setting a new standard in the precision design of therapies. The funding will primarily be channeled towards advancing our lead clinical candidate, AJ1-11095, the first Type II JAK2 inhibitor to enter clinical trials. This promising therapy is designed not only to improve therapeutic efficacy but also to overcome the limitations of current Type I JAK2 inhibitors, such as ruxolitinib, by offering a viable option for patients who have become resistant or refractory to existing treatments. Importantly, our innovative approach aims to reduce the mutant JAK2 allele burden, potentially modifying the disease course for those suffering from myelofibrosis. With this renewed financial support, Ajax Therapeutics is poised to accelerate the clinical development of next-generation JAK2 inhibitors, providing hope for patients with significant unmet needs. This milestone marks a critical step forward in transforming cancer care and ensuring that precision medicine becomes a powerful reality in the fight against MPNs.